The US FDA has granted priority review for bortezomib [Velcade] for the treatment of patients with newly diagnosed multiple myeloma (MM).

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1624, 2008-01, pp. : 23-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: A Review of its Use in Patients with Multiple Myeloma

By Curran Monique P.   McKeage Kate  

Drugs, Vol. 69, Iss. 7, 2009-05 ,pp. : 859-888

Adis International

Access to resources Recommend Favorite

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

By van de Donk Niels WCJ   Lokhorst Henk M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1569-1573

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide is effective when added to dexamethasone for the treatment of newly diagnosed multiple myeloma

By  

Inpharma, Vol. 1, Iss. 1527, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

A review of the proteasome inhibitor bortezomib in multiple myeloma

By Richardson Paul G  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1321-1331

Informa Healthcare

Access to resources Recommend Favorite

Imatinib for priority review by US FDA for GIST recurrence.

By  

Inpharma, Vol. 1, Iss. 1654, 2008-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite